Technical Analysis for BBIO - BridgeBio Pharma, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Up |
| Historical BBIO trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Crossed Above 20 DMA | Bullish | 0.00% | |
| Pocket Pivot | Bullish Swing Setup | 0.00% | |
| Volume Surge | Other | 0.00% | |
| Bollinger Band Squeeze | Range Contraction | 0.00% | |
| Multiple of Ten Bullish | Other | 0.00% | |
| Bollinger Band Squeeze | Range Contraction | 5.59% | |
| BB Squeeze + Lower Band Touch | Range Contraction | 5.59% | |
| Lower Bollinger Band Touch | Weakness | 5.59% | |
| Bollinger Band Squeeze | Range Contraction | 7.55% | |
| Fell Below 20 DMA | Bearish | 6.96% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Up 3% | about 21 hours ago |
| 10 DMA Resistance | 1 day ago |
| Up 2% | 1 day ago |
| 60 Minute Opening Range Breakout | 1 day ago |
| Rose Above 20 DMA | 1 day ago |
Free Daily (Stock) Chart Reading
- Earnings date: 08/09/2021
BridgeBio Pharma, Inc. Description
BridgeBio Pharma, Inc. engages in developing transformative medicines to treat patients who suffer from mendelian diseases. Its pipeline of 15 development programs includes product candidates from early discovery to late-stage development. The firm develops BBP-265, an oral small molecule transthyretin for the treatment of TTR amyloidosis, including cardiomyopathy and polyneuropathy manifestations; infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor for the treatment of FGFR-driven cancers and in preclinical development for the treatment of achondroplasia; and BBP-631, a preclinical adeno-associated virus, gene transfer product candidate, for the treatment of congenital adrenal hyperplasia caused by 21OHD. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly and Neil Kumar on May 17, 2019 and is headquartered in Palo Alto, CA.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Clinical Development Organ Systems Anatomy Tyrosine Kinase Receptors Tyrosine Kinase Amyloid Amyloidosis Myopathy Cardiomyopathy Fibroblast Growth Factor Receptor Hyperplasia Protein Kinase Inhibitor Transthyretin Familial Amyloid Polyneuropathy Polyneuropathy Achondroplasia Congenital Adrenal Hyperplasia TTR Amyloidosis
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 73.5 |
| 52 Week Low | 36.2 |
| Average Volume | 754,205 |
| 200-Day Moving Average | 59.39 |
| 50-Day Moving Average | 53.36 |
| 20-Day Moving Average | 50.13 |
| 10-Day Moving Average | 50.39 |
| Average True Range | 2.07 |
| ADX | 26.41 |
| +DI | 17.86 |
| -DI | 21.27 |
| Chandelier Exit (Long, 3 ATRs) | 46.18 |
| Chandelier Exit (Short, 3 ATRs) | 52.97 |
| Upper Bollinger Bands | 52.20 |
| Lower Bollinger Band | 48.06 |
| Percent B (%b) | 0.98 |
| BandWidth | 8.25 |
| MACD Line | -0.68 |
| MACD Signal Line | -0.98 |
| MACD Histogram | 0.2947 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 56.42 | ||||
| Resistance 3 (R3) | 55.96 | 54.08 | 55.70 | ||
| Resistance 2 (R2) | 54.08 | 52.98 | 54.30 | 55.46 | |
| Resistance 1 (R1) | 53.10 | 52.31 | 53.59 | 53.55 | 55.22 |
| Pivot Point | 51.21 | 51.21 | 51.46 | 51.44 | 51.21 |
| Support 1 (S1) | 50.23 | 50.12 | 50.72 | 50.69 | 49.02 |
| Support 2 (S2) | 48.35 | 49.44 | 48.57 | 48.78 | |
| Support 3 (S3) | 47.37 | 48.35 | 48.54 | ||
| Support 4 (S4) | 47.82 |
